Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Flexible insulin timing is a viable option for cystic fibrosis–related diabetes. A French clinical trial found that giving ultrafast-acting insulin after meals produced glycemic control nearly identical to standard pre-meal dosing — with no meaningful differences in time in range, A1c, or insulin dose. This could be welcome news for patients whose unpredictable eating habits make pre-meal dosing difficult.
Managing diabetes in cystic fibrosis just got a little more flexible. A phase 4 clinical trial out of France found that adults with cystic fibrosis–related diabetes (CFRD) who received ultrafast-acting insulin 20–30 minutes after meals had virtually the same glycemic outcomes as those who took standard fast-acting insulin before meals. The study, published in Diabetes Research and Clinical Practice, followed 38 patients over a full year, with each participant alternating between the two insulin-timing strategies every three months.
The results were strikingly similar across the board. Time in range — the gold-standard CGM metric — was 75.8% with pre-meal insulin vs. 74.7% with post-meal insulin, a difference so small it wasn't statistically significant. A1c levels, fasting glucose, and insulin doses were also comparable between the two approaches.
By the Numbers:
Why it matters: CFRD patients often struggle with unpredictable eating patterns, making pre-meal insulin timing impractical and raising hypoglycemia risk. Post-meal ultrafast insulin offers a more patient-friendly alternative without sacrificing glucose control.
